Capmatinib in MET-Dysregulated Advanced NSCLC: GEOMETRY Mono-1
Posted: Monday, December 7, 2020
According to research published in The New England Journal of Medicine, capmatinib showed “substantial antitumor activity” in patients with advanced non–small cell lung cancer who have an MET exon 14 skipping mutation. Rebecca S. Heist, MD, of Massachusetts General Hospital, and colleagues also found capmatinib treatment to be beneficial for some patients with MET amplification.
“It is really important that all newly diagnosed patients with NSCLC get broad molecular profiling to determine what their optimal first-line therapy should be,” noted Dr. Heist in a Massachusetts General Hospital press release.
Known as the GEOMETRY mono-1 trial, the phase II study included 364 patients with advanced NSCLC. Patients were stratified by MET status and exposure to previous therapy. All patients received 400 mg of oral capmatinib twice daily. Patients in the MET exon 14 skipping mutation cohort experienced the highest overall response rates. Among the treatment-naive patients, the overall response rate was 68%, with a median duration of response of 12.6 months. Patients who had undergone one to two previous therapy lines had an overall response rate of 41%, with a median duration of response of 9.7 months.
Patients in the MET amplification cohort who had a gene copy number of at least 10 also benefited from capmatinib treatment, with an overall response rate of 40% in those who were treatment-naive and 29% in those previously treated. However, capmatinib therapy resulted in limited efficacy in patients in this cohort whose gene copy number was less than 10, with an overall response rate in 7% to 12% of patients. The most common adverse events included peripheral edema (51%) and nausea (45%), both of which were primarily grade 1 or 2.
Disclosure: For full disclosures of the study authors, visit nejm.org.